Mesothelioma.com - Helping Mesothelioma Patients Since 1996 call

Clinical Trials — Not Recruiting

Francis Perry Wilson, MD
Reviewer: Amy Zappone
Last Updated: 10/20/2026

Mesothelioma clinical trials listed as “active, not recruiting” are still underway but are no longer enrolling new patients. People already in these studies may still be receiving treatment or follow-up care. Some of these trials have shared early results, while others have no results yet.

Learn About Mesothelioma Clinical Trials in Our Free Guide

ClinicalTrials.gov logo from the NIH U.S. National Library of Medicine

What Does “Active, Not Recruiting” Mean?

On ClinicalTrials.gov, the U.S. registry of clinical studies, “active, not recruiting” means a study is ongoing but is not enrolling new participants. People already in the study may still be receiving the treatment being tested or having follow-up exams.

Clinical trials are designed to test new treatments as efficiently as possible. Part of this design means only a certain number of patients can be accepted into each study. A study usually stops enrolling new mesothelioma patients once it reaches this target. In cancer treatment trials, follow-up can continue for years because researchers track how long patients live and whether their cancer grows or returns.

A trial that is not recruiting may not be finished or have results yet. Some trials report results from a planned early analysis while follow-up continues. For instance, the CheckMate 743 clinical trial did this in 2020. It compared the immunotherapy drugs Opdivo® (nivolumab) and Yervoy® (ipilimumab) with standard chemotherapy as a first drug treatment for pleural mesothelioma that cannot be removed with surgery. The trial has since been completed.

In results first reported in 2020 and published in The Lancet in 2021, patients who received Opdivo plus Yervoy had a median overall survival of 18.1 months. Patients who received chemotherapy had a median overall survival of 14.1 months. This means half of the patients in each group lived longer than those times.

Based on these results, the U.S. Food and Drug Administration (FDA) approved Opdivo plus Yervoy in October 2020. The approval covers adults receiving their first drug treatment for pleural mesothelioma that cannot be removed with surgery.

Researchers kept following CheckMate 743 patients after the approval. A 2026 update in the Journal of Clinical Oncology reported 5-year survival rates. The rate was 14% for patients who received Opdivo plus Yervoy and 6% for those who received chemotherapy.

Patients considering a clinical trial can find studies that are still enrolling on our Clinical Trials – Recruiting page.

Ongoing Mesothelioma Clinical Trials Not Recruiting Patients

The studies below are active but are no longer accepting new patients. Some include patients with other types of cancer or focus on topics other than treatment.

Note: The information below is provided by ClinicalTrials.gov. Select a study title to view its full details, including the conditions being studied.

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

Conditions: Mesothelioma
Last Updated: 11/16/2026
Status: Active, not recruiting

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

Conditions: Mesothelioma
Last Updated: 11/13/2026
Status: Active, not recruiting

A Beta-only IL-2 ImmunoTherapY Study

Conditions: Mesothelioma
Last Updated: 10/30/2026
Status: Active, not recruiting

Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma

Conditions: Mesothelioma
Last Updated: 10/29/2026
Status: Active, not recruiting

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

Conditions: Mesothelioma
Last Updated: 10/23/2026
Status: Active, not recruiting

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

Conditions: Mesothelioma
Last Updated: 10/20/2026
Status: Active, not recruiting

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

Conditions: Mesothelioma
Last Updated: 9/30/2026
Status: Active, not recruiting

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Conditions: Mesothelioma
Last Updated: 9/14/2026
Status: Active, not recruiting

A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma

Conditions: Mesothelioma
Last Updated: 9/11/2026
Status: Active, not recruiting

Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

Conditions: Mesothelioma
Last Updated: 8/25/2026
Status: Active, not recruiting

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

Conditions: Mesothelioma
Last Updated: 7/27/2026
Status: Active, not recruiting

A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors

Conditions: Mesothelioma
Last Updated: 6/22/2026
Status: Active, not recruiting

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

Conditions: Mesothelioma
Last Updated: 6/5/2026
Status: Active, not recruiting

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

Conditions: Mesothelioma
Last Updated: 6/1/2026
Status: Active, not recruiting

The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance

Conditions: Mesothelioma
Last Updated: 3/27/2026
Status: Active, not recruiting

A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma

Conditions: Mesothelioma
Last Updated: 3/12/2026
Status: Active, not recruiting

Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma

Conditions: Mesothelioma
Last Updated: 12/26/2025
Status: Active, not recruiting

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

Conditions: Mesothelioma
Last Updated: 11/21/2025
Status: Active, not recruiting

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Conditions: Mesothelioma
Last Updated: 8/27/2025
Status: Active, not recruiting

Sources
  1. ClinicalTrials.gov - ClinicalTrials.gov Glossary Terms; 10/19/2026

  2. ASCO Publications - Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743; 2/24/2026

  3. National Library of Medicine - FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma; 8/30/2021

  4. National Library of Medicine - First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial; 1/21/2021

Free Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide
Your Free Guide will be delivered to you within 24 hours.

What You Will Learn About

  • Mesothelioma Cancer Centers
  • Top Mesothelioma Doctors
  • Current Mesothelioma Treatments
  • Palliative Care Options
  • Mesothelioma Caregiver Information
Request a Free 2026 Mesothelioma Guide
Francis Perry Wilson, MD, Senior Medical Advisor at Mesothelioma.com
Written by Francis Perry Wilson, MD Senior Medical Advisor
Amy Zappone
Reviewed by Amy Zappone Senior Content Writer
Free mesothelioma guide for patient and and their loved ones Free Mesothelioma Guide